Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd

Equities

600671

CNE000000BF3

Pharmaceuticals

End-of-day quote Shanghai S.E. 06:00:00 2024-04-25 pm EDT 5-day change 1st Jan Change
8.89 CNY +4.59% Intraday chart for Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd +11.82% -23.76%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Qingdao Yuanjia Medical Treatment Technology proposal of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise was approved. CI
On October 19, 2023 Qingdao Yuanjia Medical Treatment Technology propose of Adding Sheng Xiaofan to the Company's Eleventh Board of Directors to Hangzhou TianMuShan Pharmaceutical Enterprise. CI
TianMuShan Pharma Elects Chairman MT
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. completed the acquisition of 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. CI
Qingdao Huilong Huaze Investment Co., Ltd. completed the acquisition of 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2023 CI
TianMuShan Pharmaceutical CFO Steps Down MT
Qingdao Huilong Huaze Investment Co., Ltd. agreed to acquire 7.98% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY 90 million. CI
Qingdao Yuanjia Medical Treatment Technology Co., Ltd. agreed to acquire 12.36% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Yongxin Huarui Cultural Development Co., Ltd. for CNY140 million. CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd announced that it expects to receive CNY 278.385575 million in funding from Qingdao Huilong Huaze Investment Co., Ltd. CI
Yongxin Huarui Proposes Board and Supervisory Board Nominations for Hangzhou Tianmushan's Board CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Auditor Raises 'Going Concern' Doubt CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Nine Months Ended September 30, 2021 CI
Hangzhou Tianmushan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Half Year Ended June 30, 2021 CI
Hangzhou Tianmushan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the First Quarter Ended March 31, 2021 CI
Hangzhou Tianmushan Pharmaceutical Enterprise Co.,Ltd Reports Earnings Results for the Full Year Ended December 31, 2020 CI
Yongxin Huarui Cultural Development Co., Ltd. completed the acquisition of 20.53% stake in Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd from Zhejiang Qingfeng Original Culture Co., Ltd. CI
Chart Hangzhou TianMuShan Pharmaceutical Enterprise Co.,Ltd
More charts
Hangzhou TianMuShan Pharmaceutical Enterprise Co., Ltd is a China based company principally engaged in the research and development, production and sales of pharmaceuticals and related health products. The Company is mainly engaged in the manufacture of chemical drug substances, processing of Chinese herbal pieces as well as the manufacture of traditional Chinese medicine preparation and Western medicine. The Company's main products are bright eye drops, FufangXianzhuliYe, amoxicillin and clavulanate potassium tablets, Hechedazao Jiaonang, Liu Wei Di Huang oral liquid, menthol, and peppermint oil. The Company mainly operates its business in the domestic market.
More about the company